Transgene SA · EURONEXT:TNG

Transgene SA — FY2005 Earnings Presentation

31 slides from Transgene SA's earnings presentation, Feb 22, 2006

  1. Slide 1: 2005: A Year of Significant Achievements Paving the Way for 2006

    2005: A YEAR OF SIGNIFICANT ACHIEVEMENTS PAVING THE WAY FOR FURTHER PROMISING DEVELOPMENTS IN 2006 Paris, February 22, 2006 London, February 24, 2006 1 transgene

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s objectives for progress in its clinical trials and product candidate development. Statements that are not historical facts are based on the Company's current expectations, beli

  3. Slide 3: Agenda

    Agenda § PART 1: 2005 ACHIEVEMENTS § PART 2: 2005 FINANCIAL RESULTS § PART 3: 2006 PERSPECTIVES § PART 4: QUESTIONS & ANSWERS 3 transgene

  4. Slide 4: 2005: A Year of Significant Achievements

    2005 : A YEAR OF SIGNIFICANT ACHIEVEMENTS § Focused strategy in therapeutic vaccination. Streamlined porfolio. § Clinical pipeline advances : üLaunch of a controlled Phase IIb clinical study with TG 4010 (MVA- MUC1-IL2). üPositive results obtained with TG 1042 (Ad-IFNγ) in cutaneous lymphoma. üPatie

  5. Slide 5: Strategic Focus: Late Stage Immunotherapeutics Portfolio

    Strategic Focus : Development of a late stage immunotherapeutics portfolio in cancer and infectious diseases § Transgene is a fully integrated biopharmaceutical company focusing on the development of immunotherapeutics for the treatment of cancer and infectious diseases. § Immunotherapeutics are alr

  6. Slide 6: Our Business Model

    Our Business Model Example of Transgene’s TG 4010 (MVA- (MVA-MUC1- MUC1-IL2) for the treatment of lung cancer – source Bryan Garnier 1 200 Project NPV Development stage N° 3: costs • High upfront & milestones payments but facing escalating 1 000 R&D costs • The commercialization rights of the produc

  7. Slide 7: Substantial Pipeline at Key Turning Point

    Substantial Pipeline at key turning point Drug Candidate Indication Preclinical Phase I Phase II Phase III New Drug Current Status Application TG 4010 Non-Small Phase II b interim (MVA- MUC1-IL2) Cell results 2007 Lung Cancer TG 4001 Prevention of Phase IIb completed (MVA –HPV-IL2) Cervical early Q2

  8. Slide 8: Key Clinical Achievements to Date

    Key Clinical Achievements to Date 8 transgene

  9. Slide 9: TG 4010 (MVA-MUC1-IL2) in lung cancer

    TG 4010 (MVA-MUC1-IL2) in lung cancer § Antigen-specific therapeutic vaccine derived Market potential from recombinant non-replicative highly § Lung cancer. First line treatment in immunogenic Modified Vaccinia Ankara (MVA) combination with chemotherapy. poxvirus containing sequences coding for the

  10. Slide 10: TG 4010 Phase IIa Results (ASCO, May 2005)

    TG 4010 (MVA-MUC1-IL2) Phase IIa Results (ASCO, May 2005) in Non Small Cell Lung Cancer Clear clinical benefit from the combination therapy as compared to the standard cisplatin/vinorelbine chemotherapy 35 evaluable patients # patients Response rate (%) Partial responses 13/35 37% Stable disease 12/

  11. Slide 11: TG 4010 Controlled Phase IIb Protocol

    TG 4010 (MVA-MUC1-IL2) in non-small cell lung cancer : controlled Phase IIb protocol § Randomized, open label, multicenter study § Principal Investigator : Professor E. Quoix § 28 centers to be opened in the European Union § Primary objective : to assess the efficacy of TG4010 combined with chemothe

  12. Slide 12: TG 4010 in NSCLC: Controlled Phase IIb

    TG 4010 (MVA-MUC1-IL2) in NSCLC: controlled Phase IIb § 140 patients multicenter controlled Phase IIb initiated Q4 2005. Recruitment expected to be completed by the beginning of Q4 2006 with first interim results due in early Q2 2007. § These results will form the basis for partnering discussions fo

  13. Slide 13: TG 4001: Preventing Cervical Cancer

    TG 4001 (MVA-HPV-IL2) : Preventing Cervical Cancer Potential market § Human Papilloma Virus 16 (HPV 16) is responsible for the development of precancerous § Prevention of cervical cancer. cervical lesions «cervical intraepithelial neoplasia Treatment of patients with precancerous of grade II/III or

  14. Slide 14: TG 4001: Current Status and Future Direction

    TG 4001 (MVA-HPV-IL2) : current status and future direction § Current Phase IIb trial in HPV 16 + patients with CIN II/III lesions § Open label study design ; 3 subcutaneous injections of 5x107 pfu § Six-month observation period to assess the efficacy of TG 4001 defined (absence of HPV-16 infection

  15. Slide 15: TG 4001: Current Status and Future Direction

    TG 4001 (MVA-HPV-IL2) : current status and future direction § Final results to be presented at the EuroGin congress in Paris (23-26 April 2006). § Accepted for an oral presentation. § These results will form the basis for partnering discussions for advanced development and commercialization of TG 40

  16. Slide 16: TG 1042 in Cutaneous Lymphoma

    TG 1042 (Ad-IFNγ) in cutaneous lymphoma § Adenoviral vector containing the human Potential market interferon gamma cytokine. § Cutaneous Lymphoma. Orphan indication. Incidence of 40 000 patients EU/US. § Immunotherapy product developed for cutaneous lymphoma, either T-cell or B-cell. § CTCL (75%) /

  17. Slide 17: TG 1042 Phase I/II Results (ASH, December 2005)

    TG 1042 (Ad-IFNγ) Phase I/II Results (ASH, December 2005) in cutaneous lymphoma Open-label multicenter, dose-escalation Phase I/II trial with 39 patients (31 evaluable) with relapsing primary cutaneous T-cell or B-cell lymphoma. Repeated monthly cycles of 3 intratumoral injections. Complete Partial

  18. Slide 18: TG 1042 Current Status and Future Direction

    TG 1042 (Ad-IFNγ) current status and future direction § IND application with the US FDA to obtain authorization to initiate a pivotal Phase study in the US filed in January 2006. § The pivotal open label, multicenter, two-step trial will enroll 41 patients with relapsing CBCL following radiotherapy

  19. Slide 19: TG 4040: Therapeutic Vaccine for Hepatitis C

    TG 4040 (MVA-HCV): therapeutic vaccine for hepatitis C chronic carriers § 170-200 M people infected worldwide ; 12 M people infected in US, EU and Japan; in France, 500 000 people infected, 50 % diagnosed, 30 % treated with 50 % efficacy. § Preclinicals ongoing. § Funding by Lyon BioPôle (€ 1.3 M ov

  20. Slide 20: Myodys

    Myodys® § Gene therapy against Duchenne Muscular Dystrophy § Fully financed by the French Association Against Muscular Dystrophy § Phase I/II planned in 2007 20 transgene

  21. Slide 21: Better Asset Valorisation to Fuel Clinical Developments

    Better asset valorisation to fuel clinical developments § Since July 2005, new bio-manufacturing contracts secured for approx. € 4.0 M. To be recognised over 2006 and 2007. § Government grants for hepatitis C project by Lyon BioPôle (Competitiveness Centre). § On-going discussions with national and

  22. Slide 22: Part 2: 2005 Financial Results

    Part 2 2005 FINANCIAL RESULTS 22 transgene

  23. Slide 23: Revenues

    Revenues IAS/IFRS; in million €; unaudited 2005 2004 Variation Manufacturing contracts 1.5 0.7 + 114 % A.F.M. 1.3 1.1 + 18 % Licenses 0.7 0.7 - R&D tax credit 0.7 0.7 - 4.2 3.2 + 28 % Contracts worth approx. € 4.0 million secured in 2005 to be received and recognised over 2006 and 2007. Others expec

  24. Slide 24: Statement of Operations

    Statement of Operations IAS/IFRS; in € million ; unaudited 2005 2004 Revenues 4.2 3.2 Operating expenses (25.7) (24.2) R&D (21.1) (20.0) G&A (4.6) (4.2) Loss from operations (21.5) (21.0) Interest income 0.4 0.4 Income tax - - Net loss (21.1) (20.6) Basic and diluted loss per share (1.74) (2.04) 24

  25. Slide 25: 2005 Cash Expenditures

    2005 Cash expenditures IAS/IFRS; in million €; unaudited 30000 25000 + 26 510 20000 + 428 +3 336 15000 +32 624 +14 650 10000 5000 0 -2 3 39 9 -5 0 0 0 -7 89 -34 0 -1 0 0 0 0 C ash, cash R e v e n u e s re c e iv e d In te r e s t in c o m e O p e r a tin g C a p ita l e x p e n d itu r e s C a pita

  26. Slide 26: July 2005 Capital Increase

    July 2005 Capital Increase § € 32.6 M raised on the European financial markets; § Warrants issued : üExercise price : € 8.05 üMaximum amount raised if all warrants exercised : € 18.7 M üBy July 2006 26 transgene

  27. Slide 27: 2006 Financial Outlook

    2006 Financial Outlook § Net cash expenditures : € 21 M to € 22 M (after sale of € 1.3 M receivables) § Significant increase in manufacturing contracts revenues and government fundings will help accelerate the clinical development of our maturing portfolio. 27 transgene

  28. Slide 28: 2006 Perspectives

    2006 Perspectives § April 2006 : The main clinical milestone in the first half of 2006 will be the release of the final Phase II results of TG 4001 (MVA- HPV-IL2) for the treatment of precancerous cervical lesions. They will be presented at the Eurogin meeting in Paris (April 23 to 26, 2006). § Mid-

  29. Slide 29: Our Vision for 2007

    Our vision for 2007: establish ourselves as a recognised leader in the field of therapeutic vaccination § By establishing corporate partnerships on our most advanced projects; § By having 3 products eligible for pivotal phase III trials; § By having received fundings from prestigious government bodi

  30. Slide 30: Today we are well on our way to meet our objectives

    Today we are well on our way to meet our objectives. 30 transgene

  31. Slide 31: Contacts Transgene

    Contacts Transgene Philippe Archinard, CEO Philippe Poncet, CFO +33 3 88 27 91 00 Transgene 67082 Strasbourg Cedex Web Site: www.transgene.fr 31 transgene

Transgene — FY2005 Earnings Presentation on 6ix